The global in vivo CRO market is experiencing significant growth due to increasing investments in drug discovery and development, growing demand for outsourced preclinical research services, and rising prevalence of chronic diseases worldwide. The global in vivo CRO market size was valued at USD 5.36 billion in 2025 and is projected to grow from USD 5.80 billion in 2026 to USD 10.89 billion by 2034, registering a CAGR of 8.2% during the forecast period (2026–2034).

The market is expanding as pharmaceutical, biotechnology, and medical device companies increasingly rely on contract research organizations (CROs) to conduct in vivo studies efficiently and cost-effectively. In vivo CROs provide specialized expertise, advanced research infrastructure, and regulatory support, enabling sponsors to accelerate drug development timelines while reducing operational complexities.

Market Drivers

One of the primary factors driving the in vivo CRO market is the increasing number of drug development programs worldwide. Pharmaceutical and biotechnology companies are investing heavily in the development of innovative therapeutics for cancer, neurological disorders, cardiovascular diseases, and rare conditions, creating strong demand for preclinical testing services.

Another significant growth driver is the growing trend toward research outsourcing. Companies are increasingly partnering with CROs to access specialized capabilities, reduce research costs, and improve operational efficiency while focusing on their core competencies.

The rising prevalence of chronic and infectious diseases is also contributing significantly to market growth. The need for effective treatment options is driving extensive preclinical research activities, increasing demand for in vivo testing and animal model services.

Furthermore, advancements in animal models, imaging technologies, and preclinical research methodologies are enhancing study accuracy and efficiency, supporting market expansion.

Market Challenges

Despite favorable growth prospects, the in vivo CRO market faces several challenges. One major restraint is the stringent regulatory environment governing animal research and preclinical testing activities. Compliance with evolving ethical standards and regulatory requirements can increase operational complexity and costs.

Another challenge is the growing pressure to reduce animal testing through alternative research methods. Regulatory agencies and advocacy groups are encouraging the adoption of in vitro and computational models, which may impact demand for certain in vivo services.

Additionally, maintaining high-quality research standards and ensuring reproducibility of study results remain critical concerns for CRO service providers.

Market Segmentation

By Service Type:

• Toxicology Studies
• Pharmacokinetics and Pharmacodynamics (PK/PD) Studies
• Safety Assessment Studies
• Efficacy Studies
• Bioanalysis Services
• Others

The toxicology studies segment dominates the market due to mandatory safety evaluations required during the drug development process.

By Animal Model:

• Rodent Models
• Non-Rodent Models
• Genetically Modified Models
• Disease-Specific Models

The rodent models segment accounts for the largest market share owing to their widespread use in preclinical research and established regulatory acceptance.

By Application:

• Oncology
• Neurology
• Cardiovascular Diseases
• Infectious Diseases
• Immunology
• Metabolic Disorders
• Others

The oncology segment holds a significant market share due to increasing cancer research activities and the growing development of targeted therapies and immunotherapies.

By End User:

• Pharmaceutical Companies
• Biotechnology Companies
• Medical Device Manufacturers
• Academic and Research Institutes

Pharmaceutical companies represent the largest end-user segment due to extensive investments in drug discovery, preclinical testing, and regulatory approval processes.

Regional Insights

North America

North America dominates the global in vivo CRO market due to strong pharmaceutical research activities, advanced healthcare infrastructure, and the presence of major CRO providers. The United States remains the largest contributor to regional market growth.

Europe

Europe represents a significant market driven by increasing pharmaceutical innovation, expanding biotechnology sectors, and growing investments in preclinical research and development activities.

Asia-Pacific

Asia-Pacific is expected to witness the fastest growth during the forecast period owing to lower research costs, expanding pharmaceutical manufacturing, increasing clinical research activities, and growing government support for life sciences innovation in countries such as China, India, Japan, and South Korea.

Latin America, Middle East, and Africa

These regions are emerging markets supported by expanding healthcare research infrastructure, growing pharmaceutical investments, and increasing outsourcing of preclinical research activities.

Key Players Analysis

The in vivo CRO market is highly competitive, with leading organizations focusing on service expansion, technological innovation, and strategic partnerships to strengthen their market positions. Key companies operating in the market include:

• Charles River Laboratories International, Inc.
• Labcorp Drug Development
• IQVIA Holdings Inc.
• Eurofins Scientific SE
• WuXi AppTec Co., Ltd.
• ICON plc
• Evotec SE
• Pharmaron Beijing Co., Ltd.
• Crown Bioscience Inc.
• Inotiv, Inc.

These companies continue investing in advanced preclinical research capabilities, specialized animal models, and integrated drug development services to meet the evolving needs of pharmaceutical and biotechnology clients worldwide.

For Detailed Insights, Visit:

https://straitsresearch.com/report/in-vivo-cro-market

About Us

Straits Research is a leading market research and intelligence organization specializing in research, analytics, and advisory services. The company provides comprehensive market reports, industry insights, and strategic business intelligence across multiple industries, helping organizations identify growth opportunities and make informed business decisions.

Contact Us

Email: sales@straitsresearch.com

Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)